Document:

<PAGE>

                             UNIT PURCHASE AGREEMENT

NexMed, Inc.
350 Corporate Boulevard
Robbinsville, New Jersey 08691

Ladies & Gentlemen:

          The undersigned purchaser (the "Purchaser") hereby confirms its
agreement with you as follows:

          1. This Unit Purchase Agreement (the "Purchase Agreement") is made by
and between NexMed, Inc., a Nevada corporation (the "Company"), and the
Purchaser as of the date this Purchase Agreement is accepted by the Company
below (the "Effective Date").

          2. This Purchase Agreement is one of a series of unit purchase
agreements of the Company relating to the offering (the "Offering") of _______
securities of the Company. In connection with the Offering, the Company's board
of directors has authorized the issuance and sale of up to a maximum aggregate
number of two million (2,000,000) units (the "Units"). Each Unit consists of
___ shares of the Company's Common Stock, par value $.001 per share (the "Common
Stock"), and a warrant (the "Warrant") to purchase ____ share of the Company's
Common Stock at an exercise price of $_____ per share, such Warrant to be
exercisable for a period of 18 months commencing six (6) months after the date
of issuance, provided, that, the number of Warrant Shares (as defined below)
shall be reduced to the extent that the Purchaser sells shares of Common Stock
of the Company issued pursuant to this Purchase Agreement during such six-month
period. Each such Warrant is redeemable by the Company at a price of $.001 per
Warrant upon notice to record holders if the closing bid price per share of the
Common Stock has been at least $_____ per share for each of the twenty (20)
consecutive trading days during a period ending on the date of the notice of
redemption all as more fully described in this Purchase Agreement, the Warrant
and accompanying documents. The minimum aggregate number of Units which must be
purchased by all investors in connection with the Offering is 250,000 Units
which shall be sold at the Initial Closing (as defined in Annex I).

          3. The Company and the Purchaser agree that the Purchaser will
purchase from the Company, and the Company will sell to the Purchaser ____
Units, at a purchase price per Unit of $____ (the "Purchase Price"), pursuant to
the Terms and Conditions for Purchase of Units attached hereto as Annex I and
incorporated herein by reference as if fully set forth herein.

          4. The Company makes no representation that this Purchase Agreement
will be accepted by the Company.

          5. The Purchaser hereby agrees not to engage, directly or indirectly,
in any short sale or third party short sales or hold a "put equivalent position"
with respect to the Common Stock (as defined in Rule 16a-1 of the Securities
Exchange Act of 1934, as amended) of the Company's Common Stock for a twenty
(20) day period prior to and for a one hundred fifty (150) day period following
the Closing Date (as defined in Annex I).

                                      -1-

<PAGE>

          Please confirm that the foregoing correctly sets forth the agreement
between us by signing in the space provided below for that purpose.

                                          PURCHASER

                                          ----------------------------------
                                          Print Name

                                          By:
                                             -------------------------------
                                          Title:
                                                ----------------------------

                                          Address:
                                                  --------------------------

                                          ----------------------------------

ACCEPTED as of August ___, 2000

NEXMED, INC.

By:
   ----------------------------------
Title:
      -------------------------------

                                      -2-

<PAGE>

                                                                      ANNEX I to
                                                                     EXHIBIT 4.2

                   TERMS AND CONDITIONS FOR PURCHASE OF UNITS

1.        Authorization and Sale of the Units.

          1.1 Authorization of the Units. The Company's board of directors has
authorized the issuance and sale of up to two million (2,000,000) units (the
"Units"), each Unit consisting of two (2) shares of the Company's Common Stock,
par value $.001 per share (the "Common Stock") and a warrant to purchase one (1)
share of the Company's Common Stock (the "Warrant") in the form attached hereto
as Exhibit 1.1.

          1.2 Sale of Units. Subject to the terms and conditions herein, the
Purchaser will purchase the number of Units agreed upon by the Purchaser at the
Purchase Price, as set forth in the Unit Purchase Agreement by and between the
Company and the Purchaser (the "Purchase Agreement"). The shares of Common Stock
sold to Purchaser pursuant to the Purchase Agreement are hereinafter referred to
as the "Initial Shares" and the shares of Common Stock arising from the exercise
of the Warrant are hereinafter referred to as the "Warrant Shares." The Initial
Shares, the Warrant and the Warrant Shares are hereinafter collectively referred
to as the "Securities."

          2.  Closing Date.

          2.1 Closing Date. The closing of the purchase and sale of the Units in
the Offering hereunder (the "Closing") shall be held at the offices of Bondy &
Schloss LLP, 6 East 43rd Street, New York, New York 10017, at 9:00 a.m. New York
time, on _______, 2000 or at such other time within five (5) business days
thereof as the Company may select. The date of the Closing of the purchase or
sale of Units in connection with the Offering is hereinafter referred to as the
"Closing Date." As of the Closing Date, the Company shall prepare a certificate
or certificates registered in the name of the Purchaser representing the Initial
Shares to be purchased by the Purchaser under the Purchase Agreement, and the
Purchaser shall send to the Company a wire transfer (in accordance with the
instructions set forth on Exhibit 2.1(a) hereto) in immediately available funds
in the amount of the purchase price of the Units to be purchased by the
Purchaser. Funds received prior to the Closing Date will not bear interest.

          2.2 Warrant Issuance. The Company will issue a Warrant to purchase one
(1) share of the Company's Common Stock at a per share exercise price of $_____
to the Purchaser as part of each Unit purchased by the Purchaser at the Closing.
The Warrant will be issued as of the Closing and the Company shall deliver the
Warrant Certificate to the Purchaser as promptly as practicable after the
Closing Date; provided, however, that the Purchaser may not exercise the Warrant
until six (6) months after the Closing Date (the "Warrant Determination Date").
The number of Warrant Shares will be reduced by any sales of Initial Shares
(including short sales and sales or purchases of derivative securities against
such Initial Shares) by the Purchaser from the Closing Date until the Warrant
Determination Date. The Company may request an affidavit and other reasonable
supporting materials as to the foregoing from any Purchaser prior to issuance of
the Warrant Shares. The Warrant is redeemable by the Company at a price of $.001
per Warrant upon notice to record holders if the closing bid price per share of
the Common Stock has been at least $____ for each of the twenty (20)
consecutive trading days during a period ending on the date of the notice of
redemption.

          3. Representations and Warranties of the Company. The Company
represents and warrants to the Purchaser as of the Closing Date as follows:

<PAGE>

          3.1 Organization and Good Standing. Each of the Company and its
subsidiaries has been duly incorporated and is validly existing as a corporation
in good standing under the laws of its jurisdiction of incorporation with full
corporate power and corporate authority to own, lease and operate its properties
and conduct its businesses as described in the SEC Documents (as defined below);
each of the Company and its subsidiaries is duly qualified to do business as a
foreign corporation and is in good standing in each jurisdiction in which the
ownership or leasing of properties or the conduct of its business as presently
conducted require such qualification, except where the failure to be so
qualified would not have a material adverse effect on the condition (financial
or otherwise), earnings, operations, or business of the Company and its
subsidiaries taken as a whole.

          3.2 Corporate Power; Authorization. The Company has all requisite
legal and corporate power and has taken all requisite corporate action to
execute and deliver the Purchase Agreement, to sell and issue the Securities and
to carry out and perform all of its obligations hereunder. The Purchase
Agreement has been duly authorized, executed and delivered on behalf of the
Company and constitutes the valid and binding agreement of the Company,
enforceable in accordance with its terms, except (i) as limited by applicable
bankruptcy, insolvency, reorganization or similar laws relating to or affecting
the enforcement of creditors' rights generally, (ii) as limited by equitable
principles generally and (iii) rights to indemnification hereunder may be
limited by applicable law.

          3.3 Validity of Securities. The Company has full corporate power and
lawful authority to sell the Units on the terms and conditions contemplated
herein, and when so sold against payment therefor as provided herein, the
Initial Shares, the Warrants and, when issued, the Warrant Shares, will be
validly authorized and issued, fully paid and nonassessable. The issuance and
delivery of each of the Initial Shares, the Warrants and the Warrant Shares is
not subject to preemptive or any similar rights of the stockholders of the
Company or any liens or encumbrances arising through the Company.

          3.4 SEC Documents; Financial Statements. The Company's Annual Report
on Forms 10-KSB for the fiscal year ended December 31, 1999 and the Company's
Quarterly Report on Forms 10-QSB for the quarterly period ended March 31, 2000,
(the "SEC Documents") as filed by the Company with the Securities and Exchange
Commission (the "Commission") have been made available to the Purchaser. The SEC
Documents conform in all material respects to the requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), as applicable, and the
rules, regulations and instructions of the Commission thereunder. The SEC
Documents did not as of their dates contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary
to make the statements made therein, in light of the circumstances in which they
were made, not misleading. The financial statements of the Company included in
the SEC Documents (the "Financial Statements") comply as to form in all material
respects with applicable accounting requirements and with the published rules
and regulations of the Commission with respect thereto. Except as may be
indicated in the notes to the Financial Statements, the Financial Statements
have been prepared in accordance with generally accepted accounting principles
consistently applied and fairly present, in all material respects, the
consolidated financial position of the Company and its subsidiaries at the dates
thereof and the consolidated results of their operations, stockholders' equity
and cash flows for the periods then ended (subject, in the case of unaudited
statements, to normal, recurring adjustments).

          3.5 Subsequent Events. Since March 31, 2000, (i) neither the Company
nor any of its subsidiaries has incurred any liabilities or obligations,
contingent or otherwise, that are material in the aggregate to the Company and
its subsidiaries, taken as a whole, except in the ordinary course of business,
and (ii) there has been no material adverse change in the condition (financial
or otherwise), earnings, operations, business of the Company and its
subsidiaries, taken as a whole, as presently conducted.

          3.6 Legal Proceedings. Except as set forth in the SEC Documents, there
are no material legal

                                      -2-
<PAGE>

proceedings pending, or to the knowledge of the Company threatened, to which the
Company or any subsidiary is a party or to which property of the Company or any
subsidiary is subject.

          3.7 Government Approval. Subject to compliance with the provisions of
applicable securities laws of state or foreign jurisdictions, no other approval
of any public body (state or federal) is or will on the Closing Date be
necessary in connection with the offer, issue and sale of the Initial Shares and
the Warrants as contemplated herein.

          3.8 No Breach. The consummation of the transactions contemplated in
the Purchase Agreement and the fulfillment of the terms hereof will not result
in a breach of any of the terms or provisions of, or constitute a default under,
the Company's Certificate of Incorporation, the Company's by-laws, or any
material indenture, mortgage, deed of trust or other agreement or instrument to
which the Company is a party or by which it is bound.

          3.9 Licenses and Consents. To the knowledge of the Company, each of
the Company and its subsidiaries is in possession of and operating in compliance
with all authorizations, licenses, certificates, consents, orders and permits
from state, federal and other regulatory authorities that are material to the
conduct of its business, all of which are valid and in full force and effect,
except to the extent that the failure to have or be in compliance with such
would not have a material adverse effect on the Company's business or results
from operations.

          3.10 Outstanding Stock. All outstanding shares of capital stock of the
Company have been duly authorized and validly issued and are fully paid and
nonassessable; all issued and outstanding shares of capital stock of each
subsidiary of the Company have been duly authorized and validly issued and are
fully paid and nonassessable.

          3.11 Intellectual Property. Except as set forth in the SEC Documents,
to the knowledge of the Company, each of the Company and its subsidiaries owns
or possesses adequate rights to use all material patents, patent rights,
inventions, trade secrets, know-how, trademarks, service marks, trade names and
copyrights which are described in the SEC Documents; except as set forth in the
SEC Documents, the Company has not received any notice of, and has no knowledge
of, any infringement of or conflict with asserted rights of the Company by
others with respect to any patent, patent rights, inventions, trade secrets,
know-how, trademarks, service marks, trade names and copyrights which, singly or
in the aggregate, if the subject of an unfavorable decision, ruling or finding,
would have a material adverse effect on the condition (financial or otherwise),
earnings, operations or business of the Company and its subsidiaries, taken as a
whole, as presently conducted; and, except as set forth in the SEC Documents,
the Company has not received any notice of, and has no knowledge of, any
infringement of or conflict with the asserted rights of others with respect to
any patent, patent rights, inventions, trade secrets, know-how, trademarks,
service marks, trade names and copyrights which, singly or in the aggregate, if
the subject of an unfavorable decision, ruling or finding, would have a material
adverse effect on the condition (financial or otherwise), earnings, operations,
or business of the Company and its subsidiaries, taken as a whole, as presently
conducted.

          3.12 Common Stock Registration. The Common Stock is registered
pursuant to Section 12(g) of the Exchange Act and is quoted on the Nasdaq
SmallCap Market and the Company has taken no action designed to, or, to the
Company's knowledge, likely to, have the effect of terminating the registration
of the Common Stock under the Exchange Act or removing the Common Stock from
quotation on the Nasdaq SmallCap Market nor has the Company received
notification that the Commission or the Nasdaq Stock Market, Inc. is
contemplating terminating such registration or quotation.

          3.13 Private Placement. The Company has not taken any action
inconsistent with the treatment of

                                      -3-
<PAGE>

the sale of the Units pursuant to the Purchase Agreement as a private placement
exempt from the registration requirements of the Securities Act of 1933, as
amended (the "Securities Act") pursuant to the provisions of Section 4(2)
thereof and Regulation D thereunder. Assuming the accuracy of the Purchaser's
representations and warranties in the Purchase Agreement and the compliance by
the Purchaser with all of its covenants and agreements, the offer, sale, and
issuance by the Company of the Units to the Purchaser as contemplated herein
constitute transactions exempt from the registration requirements of Section 5
of the Securities Act.

          4. Representations and Warranties of the Purchaser; Access to
Information; Independent Investigation. The Purchaser hereby represents and
warrants to the Company as follows:

          4.1 Investment Intent. The Purchaser is purchasing the Units for
investment for its own account only and not with a view to, or for resale in
connection with, any "distribution" thereof within the meaning of the Securities
Act. The Purchaser understands that the Securities have not been registered
under the Securities Act or registered or qualified under any state securities
law in reliance on specific exemptions therefrom, which exemptions may depend
upon, among other things, the bona fide nature of the Purchaser's investment
intent as expressed herein.

          4.2 Investment Experience. The Purchaser is an "accredited investor"
within the meaning of Rule 501 of Regulation D under the Securities Act and was
not organized for the specific purpose of acquiring the Units. The Purchaser is
aware of the Company's business affairs and financial condition and has acquired
sufficient information about the Company to reach an informed and knowledgeable
decision to acquire the Units. The Purchaser has such business and financial
experience as is required to give it the capacity to protect its own interests
in connection with the purchase of the Securities.

          4.3 Authorization. This Purchase Agreement has been duly and validly
authorized, executed and delivered on behalf of the Purchaser and is a valid and
binding agreement of the Purchaser enforceable in accordance with its terms,
subject as to enforceability to general principles of equity and to bankruptcy,
insolvency, moratorium and other similar laws affecting the enforcement of
creditors' rights generally.

          4.4 Compliance with Securities Laws and Regulations. All subsequent
offers and sales of the Securities by the Purchaser shall be made pursuant to an
effective registration statement under the Securities Act and qualification
under the applicable state securities laws or pursuant to exemptions from
registration and qualification.

          4.5 Reliance by Company. The Purchaser understands that the Units are
being offered and sold to it in reliance on specific exemptions from the
registration and qualification requirements of United States federal and state
securities laws and that the Company is relying upon the truth and accuracy of,
and the Purchaser's compliance with, the representations, warranties,
agreements, acknowledgments and understandings of the Purchaser set forth herein
in order to determine the availability of such exemptions and the eligibility of
the Purchaser to acquire the Securities.

          4.6 No Government Approval. The Purchaser understands that no United
States federal or state agency or any other government or governmental agency
has passed on or made any recommendation or endorsement of the Units.

          4.7 No Legal, Tax or Investment Advice. The Purchaser understands that
nothing in the Purchase Agreement or any other materials presented to the
Purchaser in connection with the purchase and sale of the Units constitutes
legal, tax or investment advice. The Purchaser has consulted such legal, tax and
investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its purchase of the Units.

                                      -4-

<PAGE>

          4.8 Access to Information. The Purchaser acknowledges that it has had
the opportunity to ask questions, to receive answers concerning the terms and
conditions of the Offering from the Company and to obtain any additional
information from the Company that the Company possesses or can acquire without
unreasonable effort or expense regarding the Offering, including, without
limitation, information relating to the engagement of Americal Securities, Inc.
as placement agent for a portion of the Offering pursuant to that certain fee
engagement letter agreement, dated April 7, 2000, which sets forth the cash
fees, warrants and other arrangements in connection with the Offering. In
addition, the Purchaser acknowledges that no private placement memorandum or
similar document has been prepared in connection with the Offering and the
Company has not made any representations or warranties other than as
specifically set forth herein.

          4.9 Individual Investor. If Purchaser is a natural person, Purchaser
makes the additional representations and warranties set forth on Exhibit 4.9
attached hereto

          4.10 Use of Proceeds. The Purchaser acknowledges and understands that
as set forth in the Form 10-QSB for the three months ended March 31, 2000, the
Company's current burn rate for its general corporate overhead is $400,000 per
month. Assuming the sale of all of the Units being offered hereunder, the
Company expects, with its current cash reserves, to have sufficient resources to
fund its overhead expenses, conduct the Phase III clinical studies on the
Alprox-TD cream for treating male erectile dysfunction (estimated at $15
million) and on the Femprox cream for treating female sexual arousal disorder
(estimated at $17 million), and acquire a manufacturing facility for the
Alprox-TD and Femprox products (estimated at $4 million). In the event that less
than the full number of Units being offered are sold, it will be necessary for
the Company to raise additional capital before it will be able to complete one
or more of the above studies.

          4.11 Risk and Suitability. The Purchaser acknowledges and realizes
that Purchaser's purchase of the Securities involves a high degree of risk. The
Purchaser represents that it has read and evaluated the discussion under the
heading "Risk Factors" contained in the Company's annual report on Form 10-KSB
for the year ended December 31, 1999. In addition, the Purchaser has such
knowledge and experience in business and financial matters, including, without
limitation, investment in technology companies, as will enable Purchaser to
evaluate the merits and risks of an investment in the Securities and to make an
informed investment decision. The Purchaser understands that the Company
anticipates, based on currently proposed plans and assumptions relating to its
operations, that the proceeds of this Offering will provide sufficient working
capital to meet the Company's needs for the next 3 to 12 months (depending on
the number of Units sold). In the event that the Company's plans change or its
assumptions change or prove to be inaccurate (due to unanticipated expenses,
delays, problems, difficulties or otherwise), the Company would be required to
seek additional financing sooner than anticipated. The Company has no current
arrangements with respect to, or sources of, additional financing, and it is not
anticipated that existing stockholders will provide any portion of the Company's
future financing requirements. There can be no assurance that the Company will
achieve cash flow from operations sufficient to satisfy its working capital
requirements, or at all, or that additional financing will be available to the
Company on commercially reasonable terms, or at all.

          5.  Restrictions on Transfer, Information and Registration Rights.

          5.1 Restrictions on Transferability. The Securities shall not be
transferable in the absence of a registration under the Securities Act or an
exemption therefrom, or in the absence of compliance with any term of the
Purchase Agreement. Without limiting the foregoing, (i) the Securities may be
offered, resold, pledged or otherwise transferred only (A) in a transaction
meeting the requirements of Rule 144 under the Securities Act ("Rule 144"), or
in accordance with another exemption from the registration requirements of the
Securities Act (and based upon an opinion of counsel satisfactory to the
Company) or (B) pursuant to an effective registration statement under the
Securities Act, in each case in accordance with the applicable

                                      -5-
<PAGE>

securities laws of any state of the United States or any other applicable
jurisdiction. The Company shall be entitled to give stop transfer instructions
to the transfer agent with respect to the Securities in order to enforce the
foregoing restrictions.

          5.2 Restrictive Legends. Each certificate representing any of the
Securities shall bear substantially the following legend (in addition to any
legends required under applicable securities laws).

          In the Case of All Securities:

                  THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN
                  ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE
                  SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THE
                  SECURITIES MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR
                  HYPOTHECATED UNLESS REGISTERED UNDER THE SECURITIES ACT AND
                  QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS OR UNLESS
                  SUCH SALE, TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT
                  FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND
                  THE QUALIFICATION REQUIREMENTS OF APPLICABLE STATE SECURITIES
                  LAWS OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL
                  SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION AND
                  QUALIFICATION ARE NOT REQUIRED. THE SECURITIES REPRESENTED BY
                  THIS CERTIFICATE AND THE RIGHTS OF HOLDERS THEREOF ARE SUBJECT
                  TO CERTAIN RESTRICTIONS ON TRANSFER AND OTHER RESTRICTIONS,
                  AND THE HOLDER OF THE SECURITIES REPRESENTED BY THIS
                  CERTIFICATE (INCLUDING ANY FUTURE HOLDERS) IS BOUND BY THE
                  TERMS OF A UNIT PURCHASE AGREEMENT BETWEEN THE ORIGINAL
                  PURCHASER AND THE COMPANY (COPIES OF WHICH MAY BE OBTAINED
                  FROM THE COMPANY)

          5.3 Registration on Form S-3.

              5.3.1 Filing of Registration Statement. The Company shall use its
best efforts to secure effectiveness of, as soon as practicable, and shall file
no later than sixty (60) days after the Closing Date (unless such registration
is not permitted under the applicable rules and regulations of the Commission),
a registration statement on Form S-3 (the "Registration Statement") with the
Commission under the Securities Act to register the resale of the Initial Shares
and Warrant Shares (the "Registrable Securities"); provided however, that in the
event the Company fails (due to an action or inaction of the Company) to be
eligible to file a registration statement on Form S-3, the Company shall file a
registration statement on Form S-1 or SB-2, as applicable.

              5.3.2 Registration Expenses. The Company shall pay all
Registration Expenses (as defined below) in connection with any registration,
qualification or compliance hereunder, and each holder of Registrable Securities
(the "Holders") shall pay all Selling Expenses (as defined below) and other
expenses that are not Registration Expenses relating to the Registrable
Securities resold by such Holder. "Registration Expenses" shall mean all
expenses, except for Selling Expenses, incurred by the Company in complying with
the registration provisions herein described, including, without limitation, all
registration, qualification and filing fees, printing expenses, fees and
disbursements of counsel for the Company, blue sky fees and expenses and the
expense of any special audits incident to or required by any such registration.
"Selling Expenses" shall mean all selling commissions, underwriting fees and
stock transfer taxes applicable to the Registrable Securities and all fees and
disbursements of counsel for any Holder.

                                      -6-

<PAGE>

              5.3.3 Additional Company Obligations. In the case of any
registration effected by the Company pursuant to these registration provisions,
the Company will take any and all actions necessary to: (i) keep such
registration effective until two years after the Closing Date (or such earlier
date as all of the Registrable Securities have been sold or may be sold under
Rule 144); (ii) prepare and file with the SEC such amendments and supplements to
the Registration Statement and the prospectus used in connection with the
Registration Statement as may be necessary to comply with the provisions of the
Securities Act with respect to the disposition of the Registrable Securities;
(iii) furnish such reasonable number of prospectuses and other documents
incident thereto, including any amendment of or supplement to the prospectus, as
a Holder from time to time may reasonably request; (iv) cause all such
Registrable Securities registered as described herein to be listed on each
securities exchange and quoted on each quotation service on which similar
securities issued by the Company are then listed or quoted; (v) provide a
transfer agent and registrar for all Registrable Securities registered pursuant
to the Registration Statement and a CUSIP number for all such Registrable
Securities; (vi) make reasonable efforts to comply with all applicable rules and
regulations of the Commission; and (vii) file the documents required of the
Company and otherwise use its best efforts to maintain requisite blue sky
clearance in (A) all jurisdictions in which any of the Registrable Securities
are originally sold and (B) all other states specified in writing by a Holder as
may reasonably be required to sell such Holder's Registrable Securities,
provided as to clause (B), however, that the Company shall not be required to
qualify to do business or consent to service of process in any state in which it
is not now so qualified or has not so consented.

              5.3.4 Information. Each Holder of Registrable Securities shall
furnish to the Company such information regarding such Holder and the
distribution proposed by such Holder as the Company may reasonably request in
writing and as shall be reasonably required in connection with any registration,
qualification or compliance described herein. Such Holder shall represent that
such information is true and complete.

              5.3.5 The Company shall furnish to such Holder a reasonable number
of copies of a supplement to or an amendment of such prospectus as may be
necessary so that, as thereafter delivered to the purchaser(s) of such shares,
such prospectus shall not include an untrue statement of material fact or omit
to state a material fact required to be stated therein or necessary to make the
statements therein not misleading or incomplete in the light of the
circumstances then existing.

          5.4 Indemnification and Contribution.

              5.4.1 Indemnification by the Company. The Company agrees to
indemnify and hold harmless each Holder from and against any losses, claims,
damages or liabilities (or actions or proceedings in respect thereof) to which
such Holder may become subject (under the Securities Act or otherwise) insofar
as such losses, claims, damages or liabilities (or actions or proceedings in
respect thereof) arise out of, or are based upon, any untrue statement of a
material fact contained in the Registration Statement, on the effective date
thereof; provided, however, that the Company shall not be liable in any such
case to the extent that such loss, claim, damages or liability arises out of, or
is based upon (i) an untrue statement or alleged untrue statement made in such
Registration Statement in reliance upon and in conformity with written
information furnished to the Company by or on behalf of such Holder specifically
for use in preparation of the Registration Statement or (ii) any untrue
statement in any prospectus that is corrected in any subsequent prospectus that
was delivered to the Holder prior to the pertinent sale or sales by the Holder,
and the Company will, as incurred, reimburse any Holder for any legal or other
expenses reasonably incurred in investigating, defending or preparing to defend
any such action, proceeding or claim.

              5.4.2 Indemnification by Holder. Each Holder, severally and not
jointly, agrees to indemnify and hold harmless the Company from and against any
losses, claims, damages or liabilities (or

                                      -7-
<PAGE>

actions or proceedings in respect thereof) to which the Company may become
subject (under the Securities Act or otherwise) insofar as such losses, claims,
damages or liabilities (or actions or proceedings in respect thereof) arise out
of, or are based upon an untrue statement made in such Registration Statement in
reliance upon and in conformity with written information furnished to the
Company by or on behalf of such Holder specifically for use in preparation of
the Registration Statement, provided, however, that no Holder shall be liable in
any such case for (i) any untrue statement included in any Prospectus which
statement has been corrected, in writing, by such Holder and delivered to the
Company at least three business days before the sale from which such loss
occurred or (ii) any untrue statement in any prospectus that is corrected in any
subsequent prospectus that was delivered to the Holder prior to the pertinent
sale or sales by the Holder, and each Holder, severally and not jointly, will,
as incurred, reimburse the Company for any legal or other expenses reasonably
incurred in investigating, defending or preparing to defend any such action,
proceeding or claim.

              5.4.3 Indemnification Procedures. Promptly after receipt by any
indemnified person of a notice of a claim or the beginning of any action in
respect of which indemnity is to be sought against an indemnifying person
pursuant to this Section 5.4, such indemnified person shall notify the
indemnifying person in writing of such claim or of the commencement of such
action, but the omission to so notify the indemnifying party will not relieve it
from any liability which it might have under the Purchase Agreement unless such
indemnifying party is materially prejudiced by such failure. Subject to the
provisions hereinafter stated, in case any such action shall be brought against
an indemnified person and the indemnifying person shall have been notified
thereof, the indemnifying person shall be entitled to participate therein, and,
to the extent that it shall wish, to assume the defense thereof, with counsel
reasonably satisfactory to the indemnified person. After notice from the
indemnifying person to such indemnified person of the indemnifying person's
election to assume the defense thereof, the indemnifying person shall not be
liable to such indemnified person for any legal expenses subsequently incurred
by such indemnified person in connection with the defense thereof; provided,
however, that if there exists or shall exist a conflict of interest that would
make it inappropriate in the reasonable opinion of counsel for the indemnified
person for the same counsel to represent both the indemnified person and such
indemnifying person or any affiliate or associate thereof, the indemnified
person shall be entitled to retain its own counsel at the expense of such
indemnifying person; provided, however, that in the case of the immediately
preceding proviso the indemnifying person shall not be responsible for the legal
expenses of more than one counsel for all indemnified persons.

              5.4.4 Contribution in Lieu of Indemnity. If the indemnification
provided for in this Section 5.4 is unavailable to or insufficient to hold
harmless an indemnified party under Section 5.4.1 or 5.4.2 above in respect of
any losses, claims, damages or liabilities (or actions or proceedings in respect
thereof) referred to therein, then each indemnifying party shall contribute to
the amount paid or payable by such indemnified party as a result of such losses,
claims, damages or liabilities (or actions in respect thereof), as well as any
other relevant equitable considerations based on the relative fault of the
parties. The relative fault shall be determined by reference to, among other
things, whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information
supplied by the Company on the one hand or a Holder on the other and the
parties' relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or Omission. The Company and the Holders agree
that it would not be just and equitable if contribution pursuant to this Section
5.4.4 were determined by pro rata allocation (even if the Holders were treated
as one entity for such purpose) or by any other method of allocation which does
not take account of the equitable considerations referred to above in this
Section 5.4.4. The amount paid or payable by an indemnified party as a result of
the losses, claims, damages or liabilities (or actions in respect thereof)
referred to above in this Section 5.4.4 shall be deemed to include any legal or
other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. Notwithstanding the
provisions of this Section 5.4.4, no Holder shall be required to contribute any
amount in excess of the net amount received by the Holder from the sale of the
Registrable

                                      -8-
<PAGE>

Securities to which such loss relates. No person or entity guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. The Holders' obligations in this Section 5.4.4 to
contribute are several in proportion to their respective sales of Registrable
Securities to which such loss relates and not joint.

          5.5 Reports Under the Exchange Act. With a view to make available to
the Purchaser or Holders the benefits of Rule 144 promulgated under the
Securities Act and any other rule or regulation of the SEC that may at any time
permit the Purchaser or a Holder to sell Securities to the public without
registration or pursuant to a registration on Form S-3, the Company will take
any and all action necessary to: (i) make and keep public information available,
as those terms are understood and defined in Rule 144, at all times after the
Closing; (ii) file with the SEC in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act;
and (iii) furnish to any Purchaser or Holder, so long as the Purchaser or Holder
owns any Securities forthwith upon request, (A) a written statement by the
Company that it has complied with the reporting requirements of Rule 144, the
Securities Act and the Exchange Act, (B) a copy of the most recent annual or
quarterly report of the Company, and (C) such other information as may be
reasonably requested in order to avail any Purchaser or Holder of any rule or
regulation of the SEC that permits the selling of any such Securities without
registration or pursuant to such Form S-3.

          6.  Miscellaneous.

              6.1 Waivers and Amendments. With the written consent of the
Company and the record holders of more than fifty percent (50%) of the
Securities (on a converted-to-Common Stock basis) then outstanding that have not
previously been sold in a public offering, the terms of the Purchase Agreement
may be waived or amended.

              6.2 Governing Law. This Purchase Agreement shall be governed by
and construed in accordance with the internal laws of the State of New York
without regard to its conflicts of laws principles. The Company and the
Purchaser agree to consent to the exclusive jurisdiction of the United States
District Court in New York and the Supreme Court of the State of New York, New
York County, to determine any dispute that may arise under this Purchase
Agreement or which concerns the Securities. The Purchaser further waives any
objection to venue in such State and any objection to an action or proceeding in
such State on the basis of a non-convenient forum. THE PURCHASER AGREES TO WAIVE
ITS RIGHTS TO A JURY TRIAL OR ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING
OUT OF THIS PURCHASE AGREEMENT OR ANY DOCUMENT OR AGREEMENT CONTEMPLATED HEREBY.

              6.3 Survival. The representations, warranties, covenants and
agreements made herein shall survive any investigation made by the Company or
the Purchaser and the Closing.

              6.4 Successors and Assigns. Subject to Section 5, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors,
assigns, heirs, executors and administrators of the parties hereto (specifically
including successors in interest to the Securities).

              6.5 Entire Agreement. The Purchase Agreement (including all
Exhibits thereto) constitutes the full and entire understanding and agreement
between the parties with regard to the subject hereof.

              6.6 Notices, etc. All notices and other communications required or
permitted hereunder shall be effective upon receipt and shall be in writing and
may be delivered in person, by facsimile, or nationally recognized overnight
delivery service, addressed (a) if to the Purchaser, at the address set forth on
the signature page hereof or at such other address as the Purchaser shall have
furnished the Company in

                                      -9-

<PAGE>

writing, or (b) if to the Company, at its address set forth at the beginning of
the Purchase Agreement, or at such other address as the Company shall have
furnished to the Purchaser in writing.

              6.7 Severability. If any provision of the Purchase Agreement shall
be judicially determined to be invalid, illegal or unenforceable, the validity,
legality and enforceability of the remaining provisions shall not in any way be
affected or impaired thereby.

              6.8 Titles and Subtitles. The titles of the paragraphs and
subparagraphs of the Purchase Agreement are for convenience of reference and
shall not, by themselves, determine the construction of the Purchase Agreement.

              6.9 Counterparts. The Purchase Agreement may be executed in any
number of counterparts, each of which be an original, but all of which together
shall constitute one instrument.

                                      -10-

<PAGE>

                                                                  EXHIBIT 1.1 to
                                                                     EXHIBIT 4.2

Warrant No. ____________

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT
AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
"SECURITIES ACT"). THE SECURITIES MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR
HYPOTHECATED UNLESS REGISTERED UNDER THE SECURITIES ACT AND QUALIFIED UNDER
APPLICABLE STATE SECURITIES LAWS OR UNLESS SUCH SALE, TRANSFER, ASSIGNMENT OR
HYPOTHECATION IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND THE QUALIFICATION REQUIREMENTS OF APPLICABLE STATE SECURITIES LAWS OR UNLESS
THE COMPANY RECEIVES AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION AND QUALIFICATION ARE NOT REQUIRED. THE SECURITIES REPRESENTED BY
THIS CERTIFICATE AND THE RIGHTS OF HOLDERS THEREOF ARE SUBJECT TO CERTAIN
RESTRICTIONS ON TRANSFER AND OTHER RESTRICTIONS, AND THE HOLDER OF THE
SECURITIES REPRESENTED BY THIS CERTIFICATE (INCLUDING ANY FUTURE HOLDERS) IS
BOUND BY THE TERMS OF A UNIT PURCHASE AGREEMENT BETWEEN THE ORIGINAL PURCHASER
AND THE COMPANY (COPIES OF WHICH MAY BE OBTAINED FROM THE COMPANY).

                      REDEEMABLE WARRANT TO PURCHASE SHARES
                         OF COMMON STOCK OF NEXMED, INC.

         This certifies that _______________________________________ (the
"Holder"), for value received is entitled to purchase from NexMed, Inc., a
Nevada corporation (the "Company"), ___________ (________) fully paid and
nonassessable shares of the Company's Common Stock, par value $.001 per share
(the "Warrant Shares") at a price of $_____ per share (the "Stock Purchase
Price") at any time or from time to time on or after the Commencement Date (as
defined below) up to and including 5:00 p.m. (Eastern time) on the Expiration
Date (as defined below), upon surrender to the Company at its principal office
at 350 Corporate Boulevard, Robbinsville, New Jersey 08691 (or at such other
location as the Company may advise Holder in writing) of this Warrant properly
endorsed with the Form of Subscription attached hereto duly filled in and signed
and upon payment by cash, cashier's check or wire transfer of immediately
available funds of the aggregate Stock Purchase Price for the number of shares
for which this Warrant is being exercised determined in accordance with the
provisions hereof, such exercise to be conditioned upon the accuracy of all
representations and warranties contained in such Form of Subscription. The Stock
Purchase Price and the number of shares purchasable hereunder are subject to
adjustment as provided in Section 3 of this Warrant. "Commencement Date" means
date which is six (6) months after the date of issuance of this Warrant and
"Expiration Date" means the earlier of (i) 18 months from the date hereof, (ii)
the occurrence of an event, the proposal of which is described in subsection (d)
of Section 3.4 which causes termination of this Warrant under Section 3.4, or
(iii) on the date specified in the Notice of Redemption (as defined below)
pursuant to Section 7. This Warrant is issued pursuant to the Unit Purchase
Agreement between the Company and Holder dated as of the date hereof (the
"Purchase Agreement").

          This Warrant is subject to the following terms and conditions:

          1. Exercise; Issuance of Certificates: Payment for Shares. This
Warrant is exercisable at the option of Holder at any time or from time to time
on or after the Commencement Date and prior to or on the Expiration Date for all
or a portion of the shares of Warrant Shares which may be purchased hereunder.
The

<PAGE>

Company agrees that the shares of Warrant Shares purchased under this Warrant
shall be and are deemed to be issued to Holder as the record owner of such
shares as of the close of business on the date on which this Warrant shall have
been surrendered and payment made for such shares. Subject to the provisions of
Section 2, certificates for the shares of Warrant Shares so purchased, together
with any other securities or property to which Holder is entitled upon such
exercise, shall be delivered to Holder by the Company's transfer agent at the
Company's expense within a reasonable time after this Warrant has been
exercised. Each stock certificate so delivered shall be in such denominations of
Warrant Shares as may be requested by Holder and shall be registered in the name
of Holder or such other name as shall be designated by Holder, subject to the
limitations contained in Section 2. If, upon exercise of this Warrant, fewer
than all of the shares of Warrant Shares evidenced by this Warrant are purchased
prior to the date of expiration of this Warrant, one or more new warrants
substantially in the form of, and on the terms in, this Warrant will be issued
for the remaining number of shares of Warrant Shares not purchased upon exercise
of this Warrant.

          2. Shares to be Fully Paid; Reservation of Shares. The Company
covenants and agrees that all Warrant Shares which may be issued upon the
exercise of the rights represented by this Warrant will, upon issuance, be duly
authorized, validly issued, fully paid and nonassessable and free from all
preemptive rights of any stockholder and free of all taxes, liens and charges
with respect to the issue thereof. The Company further covenants and agrees that
during the period within which the rights represented by this Warrant may be
exercised, the Company will use its best efforts to at all times have authorized
and reserved, for the purpose of issue or transfer upon exercise of this
Warrant, a sufficient number of shares of authorized but unissued Common Stock.
When and as required to provide for the exercise of the rights represented by
this Warrant, the Company will take all such action as may be necessary to
assure that such shares of Common Stock may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of any
domestic securities exchange or automated quotation system upon which the Common
Stock may be listed.

          3. Adjustment of Stock Purchase Price; Number of Shares. The Stock
Purchase Price and the number of shares of Warrant Shares purchasable upon the
exercise of this Warrant shall be subject to adjustment from time to time upon
the occurrence of certain events described in this Section 3.

             3.1 Adjustment of Purchase Price. In the event that the Company at
any time or from time to time after the issuance of this Warrant shall declare
or pay, without consideration, any dividend on the Common Stock payable in
Common Stock or in any right to acquire Common Stock for no consideration, or
shall effect a subdivision of the outstanding shares of Common Stock into a
greater number of shares of Common Stock (by stock split, reclassification or
otherwise than by payment of a dividend in Common Stock or in any right to
acquire Common Stock), or in the event the outstanding shares of Common Stock
shall be combined or consolidated, by reclassification or otherwise, into a
lesser number of shares of Common Stock, then the Stock Purchase Price in effect
immediately prior to such event shall, concurrently with the effectiveness of
such event, be proportionately decreased or increased, as appropriate. In the
event that the Company shall declare or pay, without consideration, any dividend
on the Common Stock payable in any right to acquire Common Stock for no
consideration, then the Company shall be deemed to have made a dividend payable
in Common Stock in an amount of shares equal to the maximum number of shares
issuable upon exercise of such rights to acquire Common Stock. Upon each
adjustment of the Stock Purchase Price pursuant to this Section 3.1, the holder
of this Warrant shall thereafter be entitled to purchase, at the Stock Purchase
Price resulting from such adjustment, the number of shares of Common Stock
obtained by multiplying the Stock Purchase Price in effect immediately prior to
such adjustment by the number of shares of Common Stock purchasable pursuant
hereto immediately prior to such adjustment, and dividing the product thereof by
the Stock Purchase Price resulting from such adjustment.

                                      W-2

<PAGE>

             3.2 Adjustments for Reclassification and Reorganization. If the
Common Stock shall be changed into the same or a different number of shares of
any other class or classes of stock, whether by capital reorganization,
reclassification or otherwise (other than a subdivision or combination of shares
provided for in Section 3.1), the Stock Purchase Price then in effect shall,
concurrently with the effectiveness of such reorganization or reclassification,
be proportionately adjusted so that this Warrant shall represent the right to
purchase, in lieu of the number of shares of Common Stock which this Warrant
would otherwise represent the right to purchase, a number of shares of such
other class or classes of stock equivalent to the number of shares of Common
Stock which this Warrant would have otherwise entitled the holder to purchase
immediately before that change.

             3.3 Notice of Adjustment. Upon any adjustment of the Stock Purchase
Price or any increase or decrease in the number of shares of Common Stock
purchasable upon the exercise of this Warrant, the Company shall within five
business days give written notice thereof, by first class mail, postage prepaid
(or by international delivery service, for international addresses), addressed
to the registered holder of this Warrant at the address of such holder as shown
on the books of the Company. The notice shall be signed by the Company's chief
financial officer and shall state the Stock Purchase Price resulting from such
adjustment and the increase or decrease, if any, in the number of shares
purchasable at such price upon the exercise of this Warrant, setting forth in
reasonable detail the method of calculation and the facts upon which such
calculation is based.

             3.4 Other Notices. If at any time:

                 (a) the Company shall propose to declare any cash dividend upon
its Common Stock;

                 (b) the Company shall propose to declare or make any dividend
or other distribution to the holders of its Common Stock, whether in cash,
property or other securities;

                 (c) the Company shall propose to effect any reorganization or
reclassification of the capital stock of the Company or any consolidation or
merger of the Company with or into another corporation or any sale, lease or
conveyance of all or substantially all of the property of the Company; or

                 (d) the Company shall propose to effect a voluntary or
involuntary dissolution, liquidation or winding-up of the Company;

then, in any one or more of said cases, the Company shall give, by certified or
registered mail, postage prepaid, or international delivery service for
international deliveries, addressed to the holder of this Warrant at the address
of such holder as shown on the books of the Company, (i) at least fifteen (15)
business days' prior written notice of the date on which the books of the
Company shall close or a record shall be taken for such dividend or distribution
or for determining rights to vote in respect of any such reorganization,
reclassification, consolidation, merger, sale, lease, conveyance, dissolution,
liquidation or winding-up, and (ii) in the case of any such reorganization,
reclassification, consolidation, merger, sale, lease, conveyance, dissolution,
liquidation or winding-up, at least fifteen (15) business days' written notice
of, the date when the same shall take place. Any notice given in accordance with
clause (i) above shall also specify, in the case of any such dividend or
distribution, the record date for such dividend or distribution, if after the
Commencement Date. Any notice given in accordance with clause (ii) above shall
also specify the date on which the holders of Common Stock shall be entitled to
exchange their Common Stock for securities or other property, if any,
deliverable upon such reorganization, reclassification, consolidation/merger,
sale, lease, conveyance, dissolution, liquidation or winding-up, as the case may
be and in connection with the occurrence of an event described in clause (d)
above such notice shall specify the anticipated net equity value that will
accrue to Common Stock holders so that the Holder can make an informed decision
whether or not to exercise

                                      W-3

<PAGE>

this Warrant. In the event that the Holder of the Warrant does not exercise this
Warrant prior to the occurrence of an event described in clause (a) or (b)
above, the Holder shall not be entitled to receive the benefits accruing to
existing holders of the Common Stock in such event. Upon the occurrence of an
event described in clause (c), the Holder shall be entitled thereafter, upon
payment of the Stock Purchase Price in effect immediately prior to such action,
to receive upon exercise of this Warrant the class and number of shares which
the Holder would have been entitled to receive after the occurrence of such
event had this Warrant been exercised immediately prior to such event. In
connection with the transactions described in clause (c), the Company will
require each person (other than the Company) that may be required to deliver any
cash, stock, securities or other property upon the exercise of this Warrant as
provided herein to assume, by written instrument delivered to, and reasonably
satisfactory to, the Holder of this Warrant (x) the obligations of the Company
under this Warrant and (y) the obligation to deliver to such Holder such cash,
stock, securities or other property as such Holder may be entitled to receive in
accordance with the provisions of this Section 3. Upon the occurrence of an
event the proposal of which is described in clause (d), this Warrant shall
terminate. Notwithstanding any other provision hereof, no Holder shall have the
right to obtain an injunction or restraining order or otherwise interfere with
or prevent the occurrence of any of the actions described in (a) - (d) above.

             3.5 Adjustment of Number of Warrant Shares. The number of Warrant
Shares purchasable hereunder shall be reduced on a one-for-one basis by the
number of shares of the Company's Common Stock issued to the Holder pursuant to
the Purchase Agreement and sold directly or indirectly, (including, without
limitation, any short sale, third party short sales or holdings of a "put
equivalent position" (as defined in Rule 16a-1 of the Securities Exchange Act of
1934, or amended)), from the date hereof until the Commencement Date. Upon
request by the Company, the Holder shall provide the Company with an affidavit
and other reasonable supporting materials as to the foregoing prior to issuance
of the Warrant Shares.

          4. Issue Tax. The issuance of certificates for the Warrant Shares upon
the exercise of the Warrant shall be made without charge to the Holder of the
Warrant for any issue tax in respect thereof; provided, however, that the
Company shall not be required to pay any tax which may be payable in respect of
any transfer involved in the issuance and delivery of any certificate in a name
other than that of the then Holder of the Warrant being exercised.

          5. No Voting or Dividend Rights; Limitation of Liability. Nothing
contained in this Warrant shall be construed as conferring upon the Holder
hereof the right to vote or to consent or to receive notice as a stockholder in
respect of meetings of stockholders for the election of directors of the Company
or any other matters or any rights whatsoever as a stockholder of the Company.
Except for the adjustment to the Stock Purchase Price pursuant to Section 3.2 in
the event of a dividend on the Common Stock payable in shares of Common Stock,
no dividends or interest shall be payable or accrued in respect of this Warrant
or the interest represented hereby or the shares purchasable hereunder until,
and only to the extent that, this Warrant shall have been exercised. No
provisions hereof, in the absence of affirmative action by the Holder to
purchase shares of Warrant Shares, and no mere enumeration herein of the rights
or privileges of the Holder hereof, shall give rise to any liability of such
Holder for the Stock Purchase Price or as a stockholder of the Company whether
such liability is asserted by the Company or by its creditors.

          6. Restrictions on Transferability of Securities: Compliance With
Securities Act.

             6.1 Restrictions on Transferability. The Warrant and the Warrant
Shares (collectively, the "Securities") shall not be transferable except upon
the conditions specified in the Purchase Agreement, which conditions are
intended to insure compliance with the provisions of the Securities Act and
applicable "blue sky" law.

                                      W-4
<PAGE>

             6.2 Restrictive Legend. Each certificate representing the
Securities or any other securities issued in respect of the Securities upon any
stock split, stock dividend, recapitalization, merger, consolidation or similar
event, shall (unless otherwise permitted by the provisions of the Purchase
Agreement) be stamped or otherwise imprinted with a legend substantially in the
following form (in addition to any legend required under applicable state
securities laws)

         In the Case of Warrant and Warrant Shares:

         THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR
         INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
         1933, AS AMENDED (THE "SECURITIES ACT"). THE SECURITIES MAY NOT BE
         SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS REGISTERED UNDER THE
         SECURITIES ACT AND QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS OR
         UNLESS SUCH SALE, TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT FROM
         THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND THE QUALIFICATION
         REQUIREMENTS OF APPLICABLE STATE SECURITIES LAWS OR UNLESS THE COMPANY
         RECEIVES AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
         REGISTRATION AND QUALIFICATION ARE NOT REQUIRED. THE SECURITIES
         REPRESENTED BY THIS CERTIFICATE AND THE RIGHTS OF HOLDERS THEREOF ARE
         SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND OTHER RESTRICTIONS, AND
         THE HOLDER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE (INCLUDING
         ANY FUTURE HOLDERS) IS BOUND BY THE TERMS OF A UNIT PURCHASE AGREEMENT
         BETWEEN THE ORIGINAL PURCHASER AND THE COMPANY (COPIES OF WHICH MAY BE
         OBTAINED FROM THE COMPANY).

             6.3 Exchange of Warrant. Subject to the terms and conditions
hereof, including the restrictions on transfer in this Section 6 and in the
Purchase Agreement, upon surrender of this Warrant to the Company with a duly
executed Assignment Form in the form attached hereto and funds sufficient to pay
any transfer tax, the Company shall, without charge, execute and deliver a new
Warrant or Warrants of like tenor in the name of the assignee named in such
Assignment Form and this Warrant shall promptly be canceled. The term "Warrant"
as used herein shall be deemed to include any Warrants issued in exchange for
this Warrant.

             6.4 Ownership of Warrant. The Company may deem and treat the person
in whose name this Warrant is registered as the holder and owner hereof
(notwithstanding any notations of ownership or writing hereon made by anyone
other than the Company) for all purposes and shall not be affected by any notice
to the contrary, until presentation of this Warrant for registration of transfer
as provided in Section 6.3.

          7. Redemption. This Warrant may be redeemed at the option of the
Company at a redemption price of $.001, as adjusted pursuant to Section 3 (the
"Redemption Price"), per Warrant at any time after the date hereof provided that
(i) the closing bid price of the Common Stock as reported by the Nasdaq
SmallCap(SM) market or (ii) the closing sale price, if the Common Stock is then
traded on Nasdaq/NMS or a national securities exchange, provided that such
exchange or market is the primary trading market for the Company, shall have
equaled or exceeded $____ per share (subject to adjustment in the event of any
stock splits or other events as described in Section 3.1 or 3.2 above) for each
of twenty (20) consecutive trading days during a period ending within five (5)
days prior to Redemption Notice Date (as defined below), provided, that any time
after the Redemption Notice Date (as defined below) and prior to the Redemption
Date (as defined

                                      W-5

<PAGE>

below) the Holder may exercise this Warrant, provided, further, in the event
that the Redemption Notice Date is prior to six (6) months after the date
hereof, the Commencement Date shall be deemed to be the Redemption Notice Date
and notwithstanding anything herein or in the Purchase Agreement to the
contrary, after such date the Holder may exercise this Warrant at any time prior
to the Redemption Date. The Company shall provide written notice of redemption
which shall specify the Redemption Date (the "Notice of Redemption") to the
Holder not later than five (5) days after the election of the Company to redeem
this Warrant pursuant to this Section 7. On and after the date fixed for
redemption (the "Redemption Date") which shall be no less than thirty (30) days
after the date that the Notice of Redemption is sent to the Holder (the
"Redemption Notice Date") the Holder shall have no rights with respect to this
Warrant except to receive the Redemption Price upon surrender of this Warrant
Certificate.

          8. Modification and Waiver. Except as otherwise provided herein, this
Warrant and any provision hereof may be changed, waived, discharged or
terminated only by an instrument in writing signed by the party against which
enforcement of the same is sought.

          9. Notices. Except as otherwise provided, herein, any notice, request
or other document required or permitted to be given or delivered to the holder
hereof or the Company shall be delivered or shall be sent by United States
certified or registered mail, postage prepaid, (or international delivery
service for international deliveries) to Holder at its address as shown on the
books of the Company or to the Company at the address indicated therefor in the
first paragraph of this Warrant.

         10. Descriptive Headings and Governing Law. The descriptive headings of
the several sections and paragraphs of this Warrant are inserted for convenience
only and do not constitute a part of this Warrant. This Warrant shall be
governed by and construed in accordance with the internal laws of the State of
New York without regard to its conflicts of laws principles. The Holder hereby
agrees to consent to the exclusive jurisdiction of the United States District
Court in New York and the Supreme Court of the State of New York, New York
County, to determine any dispute that may arise under this Warrant or which
concerns the Warrant Shares. The Holder further waives any objection to venue in
such State and any objection to an action or proceeding in such State on the
basis of a non-convenient forum. THE HOLDER AGREES TO WAIVE ITS RIGHTS TO A JURY
TRIAL OR ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS WARRANT
OR ANY DOCUMENT OR AGREEMENT CONTEMPLATED HEREBY.

          11. Lost Warrants or Stock Certificates. The Company represents and
warrants to Holder that upon receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction, or mutilation of any Warrant or stock
certificate and, in the case of any such loss, theft or destruction, upon
receipt of an indemnity and, if requested, bond reasonably satisfactory to the
Company, or, in the case of any such mutilation, upon surrender and cancellation
of such Warrant or stock certificate, the Company at its expense will make and
deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost,
stolen, destroyed or mutilated Warrant or stock certificate.

          12. Amendment. This Warrant is one of a series of warrants (the
"Warrant Series") to purchase, in the aggregate, up to two million (2,000,000)
shares of the Company's Common Stock. This Warrant maybe amended only with the
written approval of the Company and (i) the Holder of this Warrant or (ii) the
holders of a majority of the warrants in the Warrant Series; provided, however,
that any amendment effected pursuant to (ii) above shall be made in the same
manner to all warrants in the Warrant Series.

          13. Binding Effect; Benefits. This Warrant shall inure to the benefit
of and shall be binding upon the Company and the Holder and their respective
heirs, legal representatives, successors and assigns. Nothing in this Warrant,
expressed or implied, is intended to or shall confer on any person other than
the Company and the Holder, or their respective heirs, legal representatives,
successors or assigns, any rights,

                                      W-6
<PAGE>

remedies, obligations or liabilities under or by reason of this Warrant.

          14. Fractional Shares. No fractional shares shall be issued upon
exercise of this Warrant. The Company shall, in lieu of issuing any fractional
share, pay the Holder entitled to such fraction a sum in cash equal to such
fraction multiplied by the market price of the Common Stock, which shall be, on
any date, the closing price for the Common Stock or the closing bid if no sales
were reported, as quoted on the exchange or market that is the primary trading
market for the Company.

          IN WITNESS WHEREOF, the Company has caused this Warrant to be executed
by its officers, thereunto duly authorized this _____ day of August, 2000.

                                                      NexMed, Inc.

                                                      By:
                                                         ----------------------
                                                         Name:
                                                         Title:

                                      W-7

<PAGE>

                              FORM OF SUBSCRIPTION

                  (To be signed only upon exercise of Warrant)

To:      NexMed, Inc.

         The undersigned, the holder of the within Warrant, hereby irrevocably
elects to exercise such Warrant for, and to purchase thereunder, ______________
(__________________) shares of common stock (the "Common Stock") of NexMed, Inc.
(the "Company"), and herewith makes payment in the amount of $_______ therefore.
The certificates for such shares should be issued in the name of, and delivered
to, __________________ whose address is __________________.

         The undersigned represents, unless the exercise of this Warrant has
been registered under the Securities Act of 1933, as amended (the "Securities
Act"), that (i) the undersigned is acquiring such Common Stock for his, her or
its own account for investment and not with a view to or for sale in connection
with any distribution thereof (except for any resale pursuant to a registration
statement under the Securities Act), (ii) the undersigned has such knowledge and
experience in financial and business matters as to be capable of evaluating the
merits and risks of the undersigned's investment in the shares of Common Stock,
(iii) the undersigned has received all of the information the undersigned
requested from the Company and the undersigned considers necessary or
appropriate for deciding whether to purchase the shares, (iv) the undersigned
has the ability to bear the economic risks of the undersigned's prospective
investment and (v) the undersigned is able, without materially impairing his,
her or its financial condition, to hold the shares of Common Stock for an
indefinite period of time and to suffer complete loss on the undersigned's
investment.

         The undersigned is an "accredited investor" as defined in Regulation D
of the Securities and Exchange Commission on the date hereof.

Dated:
      -------------------

                                      ------------------------------------------
                                      (Signature must conform in all respects to
                                      name of holder as specified on the face of
                                      the Warrant)

                                      ------------------------------------------

                                      ------------------------------------------
                                      (Address)

                                      W-8

<PAGE>

THIS WARRANT AND ANY SHARES ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE
SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT FILED UNDER SUCH ACT OR PURSUANT TO AN EXEMPTION FROM REGISTRATION
UNDER SUCH ACT.

                                 ASSIGNMENT FORM

               (To be executed only upon transfer of this Warrant)

          For value received, the undersigned registered holder of the within
Warrant hereby sells, assigns and transfers unto __________________ (the
"Assignee") the right represented by such Warrant to purchase ___________
Warrant Shares and all other rights of the Holder with respect thereto under the
within Warrant, and appoints ________________ as Attorney to make such transfer
on the books of NexMed, Inc. maintained for such purpose, with full power of
substitution in the premises.

          The undersigned also represents that, by assignment hereof, the
Assignee acknowledges that this Warrant and the Warrant Shares to be issued upon
exercise hereof are being acquired for investment and that the Assignee will not
offer, sell or otherwise dispose of this Warrant or any Warrant Shares to be
issued upon exercise hereof except under circumstances that will not result in a
violation of the Securities Act of 1933, as amended, or any state securities
laws. Further, the Assignee has acknowledged that upon exercise of this Warrant,
the Assignee shall, if requested by the Company, confirm in writing, in a form
satisfactory to the Company, that the Warrant Shares so purchased are being
acquired for investment and not with a view toward distribution or resale.

Dated:
       ----------------

                                            Signature
                                                      -------------------------

                                                      -------------------------
                                                             (Print Name)

                                                      -------------------------
                                                           (Street Address)

                                                      -------------------------
                                                      (City)  (State) (Zip Code)

                                      W-9

<PAGE>

                                                              EXHIBIT 2.1(a) to
                                                                    EXHIBIT 4.2

                           WIRE TRANSFER INSTRUCTIONS:

Bank Name:         First Union National Bank

Bank ABA Number:   031201467

Bank Address:      194 Nassau Street, Princeton, NJ 08540, USA
                   Tel: 1-609-921-6000; Fax: 1-609-921-1813

Account Name:      NEXMED (USA), INC.
(Beneficiary)      350 Corporate Boulevard
                   Robbinsville, NJ 08691, USA
                   Tel: 1-609-208-9688; Fax: 1-609-208-1868

Account Number:    20-142-024-1868-8

<PAGE>

                                                                  EXHIBIT 4.9 to
                                                                     EXHIBIT 4.2

                       INVESTMENT REPRESENTATION STATEMENT

          1. Information Concerning the Company. The Purchaser represents and
warrants that the Purchaser has been provided with such information concerning
the Company that the Purchaser deems necessary and appropriate to enable the
Purchaser to evaluate the financial risk inherent in making an investment in the
Securities. The Purchaser further acknowledges that the Purchaser has received
satisfactory and complete information concerning the business and financial
condition of the Company in response to all inquiries in respect thereof.

          2. Economic Risk and Suitability. The Purchaser represents and
warrants as follows:

             2.1 The Purchaser realizes that the Purchaser's purchase of the
Securities involves a high degree of risk and will be a highly speculative
investment and that the Purchaser is able, without impairing the Purchaser's
financial condition, to hold the Securities for an indefinite period of time and
to suffer a complete loss of the Purchaser's investment.

             2.2 The Purchaser has carefully considered and has, to the extent
the Purchaser believes such discussions necessary, discussed with the
Purchaser's professional, legal, tax and financial advisors the suitability of
an investment in the Securities for the particular legal, tax and financial
situation of the Purchaser and that the Purchaser and/or the Purchaser's
advisors have determined that the Securities are a suitable investment for the
Purchaser.

             2.3 The Purchaser has such knowledge and experience in business and
financial matters as will enable the Purchaser to evaluate the merits and risks
of an investment in the Securities and to make an informed investment decision.

             2.4 The Purchaser has carefully read this Agreement and the Company
has made available to the Purchaser or the Purchaser's advisors all information
and documents requested by the Purchaser relating to investment in the
Securities, and has provided answers to the Purchaser's satisfaction to all of
the Purchaser's questions concerning the Company and the Securities to be
acquired.

             2.5 The Purchaser understands that neither the Company nor any of
its officers/directors, has any obligation to register the Securities under any
federal or state securities act or law except as otherwise expressly set forth
in Section 5 of the Purchase Agreement.

             2.6 All information that the Purchaser has provided concerning
himself or herself, his or her financial position and (each of) his or her
representative(s), if any, is correct and complete as of the date set forth
below, and if there should be any material change in such information, the
Purchaser will provide such information to the Company as soon as practicable
thereafter.

             2.7 The Purchaser understands that the Company is relying on the
truth and accuracy of the declarations, representations, warranties and
agreements made by the Purchaser to the Company herein in transferring the
Securities to the Purchaser.

             2.8 The Purchaser confirms that the Purchaser has received no
general solicitation or general advertisement and has attended no seminar or
meeting (whose attendees have been invited by any general solicitation or
general advertisement) and has received no advertisement, article, notice or
other communication published in any newspaper, magazine, or similar media or
broadcast or television or radio regarding the Offering.

<PAGE>

          3. Status of Purchaser. The Purchaser represents and warrants that the
Purchaser is an "Accredited Investor", as defined in Rule 501 of Regulation D
under the Securities Act of 1933, as amended, because the Purchaser is either:

             (a)  A natural person whose individual net worth, or joint net
                  worth with that person's spouse, at the time of his/her
                  purchase, exceeds $1 million; or

             (b)  A natural person who had individual income in excess of
                  $200,000 in each of the two most recent years or joint
                  income with that person's spouse in excess of $300,000 in
                  each of those years and has a reasonable expectation of
                  reaching the same income level in the current year.

          4. Residency. The undersigned is a bona fide resident of ____________.CONSENT OF SWIDLER BERLIN SHEREFF FRIEDMAN, LLP

We hereby consent to the reference to our firm included in the prospectus and
statement of additional information of Merrill Lynch Strategic Dividend Fund filed as part of
Registration Statement No. 33-14517 and to the use of our opinion of counsel, incorporated by
reference to Exhibit 10(b) to Post-Effective Amendment No. 2 to the Registration Statement on
Form N-1A (File No. 33-14517).

                            
                            
                            
                            
Swidler Berlin Shereff Friedman, LLP

New York, New York
September 29, 2000
                        
                            
                            

/s/  Swidler Berlin Shereff Friedman, LLP

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]